The Integrin alpha 9beta 1 Mediates Adhesion to Activated Endothelial Cells and Transendothelial Neutrophil Migration through Interaction with Vascular Cell Adhesion Molecule-1

Yasuyuki Taooka,* John Chen,* Ted Yednock,Dagger and Dean Sheppard*

* Lung Biology Center, Center for Occupational and Environmental Health, Cardiovascular Research Institute and the Department of Medicine, University of California, San Francisco, California 94143; and Dagger  Elan Pharmaceuticals, South San Francisco, California 94080

    Abstract
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

The integrin alpha 9beta 1 has been shown to be widely expressed on smooth muscle and epithelial cells, and to mediate adhesion to the extracellular matrix proteins osteopontin and tenascin-C. We have found that the peptide sequence this integrin recognizes in tenascin-C is highly homologous to the sequence recognized by the closely related integrin alpha 4beta 1, in the inducible endothelial ligand, vascular cell adhesion mole-cule-1 (VCAM-1). We therefore sought to determine whether alpha 9beta 1 also recognizes VCAM-1, and whether any such interaction would be biologically significant. In this report, we demonstrate that alpha 9beta 1 mediates stable cell adhesion to recombinant VCAM-1 and to VCAM-1 induced on human umbilical vein endothelial cells by tumor necrosis factor-alpha . Furthermore, we show that alpha 9beta 1 is highly and selectively expressed on neutrophils and is critical for neutrophil migration on VCAM-1 and tenascin-C. Finally, alpha 9beta 1 and alpha 4 integrins contribute to neutrophil chemotaxis across activated endothelial monolayers. These observations suggest a possible role for alpha 9beta 1/VCAM-1 interactions in extravasation of neutrophils at sites of acute inflammation.

Key words: integrin;  alpha 9beta 1;  alpha 4;  neutrophil migration;  vascular cell adhesion molecule-1
    Introduction
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

INTEGRINS are heterodimeric receptors for extracellular matrix and cell surface counter-receptors which play important roles in embryonic development, inflammation, wound healing, and tumorigenesis (Hynes, 1987, 1992; Ruoslahti and Pierschbacher, 1987). Integrin ligand-binding specificity is determined by structural features of each subunit, but there is considerable ligand-binding overlap among integrin heterodimers. One clue to ligand-binding overlap has been the degree of sequence homology among integrin alpha  subunits. For example, the integrin alpha  subunits alpha 5, alpha v, alpha IIbeta , and alpha 8 are all closely related, and integrin heterodimers containing these alpha  subunits recognize ligands containing the peptide sequence arginine-glycine-aspartic acid (Hynes, 1992; Schnapp et al., 1995). Similarly, the alpha m, alpha L, and alpha x subunits are highly homologous to one another and recognize closely related immunoglobulin family members as ligands (Hynes, 1992). We previously cloned and sequenced the integrin alpha 9 subunit, and have shown that it forms a single integrin heterodimer, alpha 9beta 1 (Palmer et al., 1993). The alpha 9 subunit cDNA sequence is 41% identical to the integrin alpha 4 subunit sequence, but <= 27% identical to any other integrin subunit, identifying alpha 9 and alpha 4 as sole members of a subfamily of integrin alpha  subunits.

In an effort to understand the structural basis of alpha 9beta 1 ligand-binding in more detail, we recently mapped the alpha 9beta 1 ligand-binding site in the extracellular matrix protein tenascin-C (Yokosaki et al., 1994). alpha 9beta 1 binds to a single exposed loop in the third fibronectin type III repeat of tenascin-C (B-C loop) to a minimal sequence EIDGIEL (Schneider et al., 1998; Yokosaki et al., 1998). We noticed that a critical portion of this sequence (IDG) is homologous to the tripeptide sequence IDS present in the previously mapped ligand-binding site for the alpha 4beta 1 ligand, vascular cell adhesion molecule-1 (VCAM-11; Clements et al., 1994; Yokosaki et al., 1998). Therefore, we undertook the current study to determine whether alpha 9beta 1 recognizes VCAM-1 as a ligand and whether or not any such interaction is biologically significant.

    Materials and Methods
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Reagents

BSA, formyl-methionylleucylphenylalanine (FMLP), and dextran were purchased from Sigma Chemical Co. Recombinant human tumor necrosis factor (TNF)-alpha , recombinant human interferon (IFN)-gamma (specific activity of 107 U/mg), and recombinant interleukin 8 (IL-8) were obtained from R&D Systems, Inc. Fluorescent reagent, 2',7'-bis-(carboxyethyl)-5,6-carboxy-fluorescein acetoxymethyl ester (BCECF-AM) was purchased from Molecular Probes, Inc. A recombinant form of the third fibronectin type III repeat of chicken tenascin-C (Prieto et al., 1993) containing alanine substitution mutations within the RGD site (TNfn3RAA), was obtained from Anita Prieto and Kathryn Crossin (Scripps Research Institute, La Jolla, CA) and prepared in Escherichia coli. A recombinant VCAM-1/IgG chimera (Yednock et al., 1995) was produced in baculovirus as previously described. Recombinant intercellular adhesion molecule-1 (ICAM-1)-Ckappa fusion protein was a gift from B. Imhof (Centre Medicale Universitaire, Geneva, Switzerland) to D. Erle (University of California, San Francisco, CA). Ficoll-hypaque plus for isolation of neutrophils from venous blood was purchased from Pharmacia Biotech, Inc. and used according to the manufacturer's specifications.

Antibodies, Cells, and Cell Culture

Mouse mAbs, Y9A2 against human alpha 9beta 1 (Wang et al., 1996) and AN100226M (100226) against alpha 4 (Kent et al., 1995), were prepared as previously described. Mouse mAbs, W6/32 against human MHC and IB4 against the integrin beta 2 subunit, were prepared from hybridomas obtained from American Type Tissue Collection. Mouse monoclonal antihuman VCAM-1 (CD106) was purchased from R&D Systems. FITC-labeled mouse monoclonal anti-CD16 antibody was purchased from Caltag. Human umbilical vein endothelial (HUVE) cells were purchased from Clonetics and grown in endothelial cell growth media (EGM) containing 2% FBS, 10 ng/ml human recombinant EGF, 50 µg/ml gentamycin, 50 ng/ ml amphotericin B, 12 µg/ml bovine brain extract, and 1 µg/ml hydrocortisone and were used between passage 3 and 10. alpha 9- and mock-transfected SW480 and CHO cells were generated by transfection with the previously described full-length alpha 9 expression plasmid pcDNAIneoalpha 9 (Yokosaki et al., 1994) or the empty vector pcDNAIneo (Invitrogen Corp.) by calcium phosphate precipitation. Transfected cells were maintained in Dulbecco's minimal essential medium(DMEM) supplemented with 10% FCS and the neomycin analogue G-418 (1 mg/ml; Life Technologies, Inc.). Both cell lines continuously expressed high surface levels of alpha 9beta 1 as determined by flow cytometry with Y9A2 (Yokosaki, 1996, 1998).

Flow Cytometry

Cultured cells were harvested by trypsinization and rinsed with PBS. Nonspecific binding was blocked with normal goat serum at 4°C for 10 min. Cells were then incubated with primary antibodies (unconjugated or conjugated with FITC) for 20 min at 4°C, followed by secondary antibodies conjugated with phycoerythrin (Chemicon International, Inc.). Between incubations, cells were washed twice with PBS. The stained cells were resuspended in 100 µl of PBS and fluorescence was quantified on 5,000 cells with a FACScan® (Becton Dickinson and Co.).

Immunoprecipitation and Western Blotting

Cells were lysed in immunoprecipitation buffer (100 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM CaCl2, 1% Triton X-100, 0.1% SDS, and 0.1% NP-40) supplemented with 10 µg/ml pepstatin (Sigma Chemical Co.), 10 µg/ml leupeptin, 5 µg/ml aprotinin (Calbiochem-Novabiochem Corp.), and 1 mM phenylmethylsulfonyl fluoride (Sigma Chemical Co.). Human neutrophils (107) were incubated with 1 mM diisopropyl flurophosphate (Sigma Chemical Co.) for 15 min before cell lysis. After preclearing with protein G-Sepharose, the supernatant was incubated with primary antibody for 2 h at 4°C and immune complexes were captured by protein G-Sepharose for 45 min at 4°C. The beads were washed five times, and boiled in 2.5× nonreducing Laemmli sample buffer, and samples were separated by SDS-PAGE on 7.5% gels under reducing conditions and transferred to Immobilon membranes. Membranes were blocked with 4% casein, incubated with affinity-purified anti-alpha 9 cytoplasmic domain antiserum 1057 (Palmer et al., 1993), and developed with luminol.

Cell Adhesion Assays

Wells of nontissue culture treated polystyrene 96-well flat bottomed microtiter plates (Nunc Inc.) were coated by incubation with 100 µl VCAM-1/Ig or TNfn3RAA for 1 h at 37°C. After incubation, wells were washed with PBS, then blocked with 1% BSA in DMEM at 37°C for 30 min. Control wells were filled with 1% BSA in DMEM. SW480 or CHO cells were detached using trypsin/EDTA and resuspended in serum-free DMEM. For blocking experiments, cells were incubated with 10 µg/ml Y9A2 and/ or 100226, for 15 min at 4°C before plating. The plates were centrifuged (top side up) at 10 g for 5 min before incubation for 1 h at 37°C in humidified 5% CO2. Nonadherent cells were removed by centrifugation (top side down) at 48 g for 5 min. Attached cells were fixed with 1% formaldehyde and stained with 0.5% crystal violet, and the wells were washed with PBS. The relative number of cells in each well was evaluated after solubilization in 40 µl of 2% Triton X-100 by measuring the absorbance at 595 nm in a microplate reader (Bio-Rad Laboratories). All determinations were carried out in triplicate.

For adhesion assays on HUVE cells, confluent monolayers of HUVE cells were prepared in 96-well plates in 250 µl of EGM with 2% FBS. Plates were washed twice with serum-free DMEM, then stimulated for 24 h at 37°C with TNF-alpha (3 ng/ml) or IFN-gamma (3 ng/ml) in serum-free DMEM. SW480 cells were detached using trypsin/EDTA and labeled with 2 µM BCECF-AM at room temperature for 30 min. Then cells were washed three times with serum-free DMEM and incubated with blocking antibody, Y9A2 (10 µg/ml), 100226 (10 µg/ml), or combinations of these antibodies for 15 min on ice. In some experiments, HUVE cells were incubated with CD106 (5 µg/ml) for 15 min at 37°C. 50,000 cells in 200 µl of serum-free DMEM were added to each well, and plates were centrifuged at 20 g for 5 min, and covered with aluminum foil to prevent photobleaching. Plates were then incubated for 60 min at 37°C in 5% CO2. After incubation, nonadherent cells were removed by washing twice with serum-free DMEM. Finally, 200 µl of the same medium was added to each well, and fluorescence was quantified with a fluorometer (Fluoroskan II; Labsystems) at excitation wavelength 485 nm and emission wavelength 538 nm. The adherent ratio (%) was calculated as follows: (fluorescence from experimental sample - fluorescence from negative control samplediv  total fluorescence added to chamber. All determinations were carried out in triplicate.

Neutrophil Migration Assays

Neutrophils were purified from human peripheral venous blood containing 20 U/ml of heparin. Neutrophils were isolated by ficoll-hypaque density gradient centrifugation, followed by 3% dextran sedimentation (Gresham et al., 1986). Erythrocytes were subjected to hypotonic lysis, remaining neutrophils were washed and resuspended in PBS. The isolated neutrophils were >95% pure and >95% viable as assessed by Wright-Giemsa staining and trypan blue exclusion, respectively. Cell migration was analyzed essentially as described by Marks et al. (1991). In brief, glass coverslips were placed in 35-mm culture dishes and incubated with 100 µl serum-free media containing 10 µg/ml VCAM-1/Ig, 10 µg/ml TNfn3RAA, and 5 µg/ml of ICAM-1 or 1% BSA for 60 min at 37°C, washed, and then incubated with 1% BSA for 30 min. Neutrophils were incubated with no antibody, Y9A2 (10 µg/ml), 100226 (10 µg/ml), IB4 (20 µg/ml), or combinations of antibodies for 15 min at 4°C, and were then incubated for 10 min at 37°C with or without 10 nM FMLP. 104 cells were plated onto the coverslip area of each well and allowed to attach at 37°C for 5 min. Dishes were then placed on a videomicroscope stage and individual fields (200×) were recorded for 3 min. Three different fields were examined in each chamber. To count the number of migrating cells in a given field, outlines were made of each cell. Cells were considered to have migrated when both the leading edge and tail of the cell moved >= 7 µm from their initial position. At least 40 neutrophils were analyzed per field and the ratio of migrating to total cells was calculated.

Neutrophil Transmigration Assays

Transendothelial neutrophil migration was assessed as described by Cooper et al. (1995). HUVE cells were plated onto polycarbonate inserts (Transwell, 6.5-mm diameter, 8-µm pore for 24-well plate; Costar Corp.) in 200 µl of serum-containing EGM, and allowed to grow to confluence over 72 h. 500 µl serum-free DMEM was added to the lower chamber of each well. 24 h before addition of neutrophils, upper chambers were washed twice with serum-free media and new medium with or without 3 ng/ml of TNF-alpha . Immediately before the addition of neutrophils, the upper chambers were washed twice with serum-free DMEM and medium in the lower chamber was replaced with 500 µl serum-free DMEM or serum-free DMEM with 10 nM FMLP or 50 ng/ml IL-8. In some experiments HUVE cells were incubated with CD106 (5 µg/ml) at 37°C for 15 min. Purified neutrophils were incubated with no antibody, Y9A2 (10 µg/ml), 100226 (10 µg/ml), IB4 (20 µg/ml), W6/32 (10 µg/ml), or combinations of antibodies for 15 min at 4°C, and 2 × 105 cells in 200 µl of media were added to each upper chamber. After 3 h at 37°C in 5% CO2, nonadherent cells in the upper chamber were removed. Medium, including migrated neutrophils from the lower chamber, was collected, the lower chamber was rinsed several times to collect all the neutrophils that had transmigrated, and the absence of additional adherent neutrophils was confirmed microscopically. The medium and all washes were pooled and resuspended, and cells were counted with a hemocytometer. All determinations were carried out in duplicate and repeated at least twice.

    Results
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

alpha 9beta 1 Mediates Static Adhesion of Resting alpha 9-transfected SW480 Cells and CHO Cells to VCAM-1

To determine whether VCAM-1 could function as a ligand for alpha 9beta 1, we performed cell adhesion assays with two different cell lines, SW480 and CHO, that had been stably transfected with either an alpha 9-expression plasmid or empty vector. Both cell lines stably expressed alpha 9beta 1 on the cell surface as demonstrated by flow cytometry with the anti-alpha 9beta 1 antibody Y9A2 (Fig. 1, A and B). Adhesion assays were performed on plates coated with either the known alpha 9beta 1 ligand, recombinant TNfn3RAA (Fig. 1, C and D), or recombinant VCAM-1/Ig (Fig. 1, E and F). For both cell lines, alpha 9-transfectants adhered to both TNfn3 and to VCAM-1 in a concentration-dependent manner, whereas mock-transfectants did not adhere to either substrate. Adhesion of each alpha 9-transfected cell line was completely inhibited by the anti-alpha 9beta 1 antibody, Y9A2, demonstrating that this effect was mediated by alpha 9beta 1.


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 1.   Adhesion of alpha 9- and mock-transfected SW480 and CHO cells to TNfn3RAA or VCAM-1. Flow cytometric evaluation of cell surface expression of integrin alpha 9 on CHO cells (A), or SW480 cells (B). Open peaks represent fluorescence of mock-transfected cells and shaded peaks represent fluorescence of alpha 9-transfected cells stained with anti-alpha 9beta 1 antibody, Y9A2. alpha 9- or mock-transfected CHO (C and E) or SW480 cells (D and F) were added to 96-well plates coated with a range of concentrations of TNfn3RAA (C and D) or VCAM-1/Ig (E and F). Cells were allowed to attach for 1 h, nonadherent cells were removed by centrifugation, and adherent cells were stained with crystal violet and quantified by measurement of absorbance at 595 nm. Data for a typical experiment are shown and are expressed as the mean (+ SD) of triplicate measurements for untreated alpha 9-transfected cells (squares), untreated mock-transfected cells (circles), alpha 9-transfected cells treated with Y9A2 (10 µg/ml; diamonds), and mock-transfected cells treated with Y9A2 (10 µg/ml; triangles). Similar results were obtained in four separate experiments.

alpha 9beta 1 Mediates Adhesion to TNF-alpha -activated, but not to IFN-gamma -activated HUVE Cells, Via Interaction with Induced VCAM-1

To determine whether alpha 9beta 1-mediated adhesion to VCAM-1 was biologically significant, we next examined the role of this integrin in adhesion of cells to resting HUVE cells, and to HUVE cells that had been activated by incubation with TNF-alpha (3 ng/ml), a well characterized inducer of VCAM-1 expression, or IFN-gamma (3 ng/ml), a cytokine that does not induce VCAM-1 expression. The effects of each cytokine on VCAM-1 expression under the conditions used in these experiments were examined by flow cytometry with anti-VCAM-1 antibody CD106 (Fig. 2, B-D). As expected, resting HUVE cells (Fig. 2 B) and HUVE cells stimulated with IFN-gamma (Fig. 2 D) did not express detectable levels of VCAM-1, but VCAM-1 was dramatically induced by TNF-alpha (Fig. 2 C). All cell lines examined demonstrated baseline adhesion to resting HUVE cells, and demonstrated a similar level of adhesion to HUVE activated by IFN-gamma , and this baseline adhesion was unaffected by anti-alpha 9beta 1 antibody (Fig. 2 A). However, only alpha 9-transfected cells demonstrated enhanced adhesion to TNF-alpha -treated HUVE. This enhanced adhesion was returned completely to basal levels by antibody to either alpha 9beta 1(Y9A2) or to VCAM-1 (CD106), demonstrating that it was due to an interaction between alpha 9beta 1 and VCAM-1.


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 2.   Adhesion of alpha 9- or mock-transfected SW480 cells to HUVE cells. (A) Confluent monolayers of HUVE cells were incubated for 24 h with medium alone (no activation), TNF-alpha (3 ng/ml), or IFN-gamma (3 ng/ml). Fluorescently labeled alpha 9- or mock-transfected SW480 cells were allowed to adhere to HUVE cell monolayers for 60 min in the presence or absence of the alpha 9beta 1 blocking antibody Y9A2 (10 µg/ ml) or the VCAM-1 blocking antibody CD106 (5 µg/ml). Nonadherent cells were removed by gentle washing and the percent of adherent cells was calculated based on fluorescence. Data are presented as the mean (+ SD) of triplicate measurements. Similar results were obtained in two separate experiments. Flow cytometric evaluation of cell surface expression of VCAM-1 on HUVE cells treated with medium alone (B), TNF-alpha (3 ng/ml; C), or IFN-gamma (3 ng/ml; D). Open peaks represent fluorescence of unstained HUVE cells and shaded peaks represent fluorescence of cells stained with the anti-VCAM-1 antibody, CD106.

alpha 9beta 1 Is Expressed on Neutrophils

We have previously demonstrated that alpha 9beta 1 is widely expressed on epithelial and smooth muscle cells (Palmer et al., 1993), but expression on leukocytes has not been reported. To determine whether alpha 9beta 1 is expressed on cells likely to encounter activated endothelial cells, we performed flow cytometry on whole blood leukocytes with the alpha 9beta 1 antibody Y9A2. We evaluated expression on neutrophils, monocytes, and lymphocytes by gating on each population separately, based on differential light scattering. From a separate atopic donor we evaluated expression on eosinophils, which were separated from other leukocytes based on light scattering and the absence of surface expression of CD16. In parallel, we examined expression of the structurally related integrin subunit, alpha 4. alpha 9beta 1 was not detected on lymphocytes or eosinophils and was expressed at low levels on monocytes (Fig. 3 A). In contrast, alpha 9beta 1 was highly and uniformly expressed on human neutrophils. As expected, alpha 4 was highly expressed on lymphocytes, monocytes, and eosinophils, but was also detected on neutrophils, albeit at considerably lower levels.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 3.   Expression of alpha 4 or alpha 9 integrins on leukocytes. (A) Whole blood leukocytes were stained with control antibody E7P6 that recognizes alpha vbeta 6, an integrin not expressed on leukocytes (unshaded peaks), Y9A2 against alpha 9beta 1, or 100226 against alpha 4 (shaded peaks). Fluorescence of lymphocytes, neutrophils, eosinophils, and monocytes were analyzed separately by gating on each population on the basis of a plot of forward versus side scattering of light. Fluorescence of eosinophils was analyzed from separate atopic donor by gating on eosinophils based on light scattering and the absence of expression CD16. (B) Western blot with anti-alpha 9 antiserum 1057 of lysates of human neutrophils that had been immunoprecipitated with anti-alpha 9beta 1 antibody Y9A2 or the control antibody R6G9 against the irrelevant integrin alpha vbeta 6 (lane 2). The expected molecular mass of the alpha 9 subunit (160 kD) is shown by the lefthand arrow. The position of molecular size marker (kD) is shown to the right.

Expression of alpha 9 on neutrophils was further confirmed by immunoprecipitation with Y9A2 followed by Western blotting with an affinity-purified antiserum raised against a unique portion of the alpha 9 cytoplasmic domain. A band of 160 kD (appropriate molecular mass for alpha 9) was detected in lysate of human neutrophils after immunoprecipitation with Y9A2, but not after immunoprecipitation with the control antibody R6G9 (Fig. 3 B).

alpha 9beta 1 Mediates Migration of FMLP-activated Neutrophils on TNfn3 or VCAM-1

To determine whether alpha 9beta 1 expression on neutrophils was biologically significant, we initially sought to examine static adhesion of neutrophils to dishes coated with either TNfn3RAA or VCAM-1. However, in the absence of antibodies against beta 2 integrins, neutrophils avidly adhered to all surfaces examined, and in the presence of beta 2 integrin blocking antibodies, neutrophils could not be induced to adhere to either VCAM-1 or TNfn3RAA by incubation with MnCl2, FMLP, phorbol esters, or the beta 1 activating antibody TS2/16 (data not shown). Therefore, we examined the possible role of alpha 9beta 1 in another important neutrophil function, cell migration. Migration was examined by counting the numbers of individual neutrophils that migrated on chambers coated with either TNfn3RAA or VCAM-1 in the presence or absence of the activating agonist FMLP (10 nM). In the absence of FMLP, very few neutrophils migrated on either substrate (Fig. 4 A), and antibodies against alpha 9beta 1, alpha 4, or beta 2 integrins had no effect. In the presence of FMLP, neutrophil migration was significantly enhanced on TNfn3RAA, an effect that was abolished by antibody against alpha 9beta 1. FMLP also enhanced neutrophil migration on VCAM-1, and this effect was partially inhibited by antibodies against alpha 9beta 1 or alpha 4, and completely inhibited by the combination of both antibodies. These data demonstrate a significant role for alpha 9beta 1 in mediating neutrophil migration on both substrates. Antibody against beta 2 integrins had no effect on neutrophil migration on FMLP-induced neutrophil migration on TNfn3RAA or VCAM-1. However, as expected, antibody against beta 2 inhibited FMLP-induced migration on the beta 2 integrin ligand ICAM-1, whereas antibodies against alpha 9beta 1 or alpha 4 had no effect (Fig. 4 B).


View larger version (47K):
[in this window]
[in a new window]
 
Fig. 4.   Neutrophil migration on VCAM-1 or TNfn3RAA. Neutrophils were allowed to migrate on glass coverslips coated with: (A) 1% BSA or TNfn3RAA (10 µg/ml); or (B) VCAM-1 (10 µg/ml) or ICAM-1 (5 µg/ml), for 3 min in the presence or absence of FMLP (10 nM), and in the presence of: no antibody; alpha 9beta 1 antibody, Y9A2 (10 µg/ml); alpha 4 antibody, 100226 (10 µg/ml); antibody IB4 (20 µg/ml); or the combination of these antibodies. The percentage of migrating cells was determined by analyzing >= 40 cells from each of three microscopic fields, and is expressed as the mean (+ SD) of triplicate values from two separate experiments.

alpha 9beta 1 Mediates Migration of Neutrophils through Activated HUVE Cell Monolayers

We next sought to determine whether the effect of alpha 9beta 1 and alpha 4 integrin(s) described above was relevant to an in vitro model of neutrophil extravasation-migration across endothelial monolayers. HUVE cells were grown to confluence on the top side of permeable filter supports and incubated in the presence or absence of TNF-alpha (3 ng/ml). Purified neutrophils were added to the apical compartment in the presence or absence of FMLP added to the basal compartment. These studies were performed in the absence of blocking antibodies, or in the presence of antibodies against alpha 9beta 1, alpha 4, beta 2, VCAM-1, control antibody against MHC, or combinations of these antibodies. As expected, in the absence of blocking antibodies, FMLP greatly increased neutrophil migration into the bottom compartment, and this effect was augmented by pretreatment of HUVE cells with TNF-alpha (Fig. 5 A). No antibody affected basal migration across unstimulated HUVE cells or FMLP-induced migration across unstimulated HUVE cells (Fig. 5 B). However, antibody against either alpha 9beta 1 or alpha 4 inhibited the augmented migration induced by TNF-alpha . Antibody against VCAM-1 was equally effective in inhibiting migration across TNF-alpha -treated HUVE cells, suggesting that TNF-alpha augmented transmigration was mediated by an interaction between alpha 9beta 1 and alpha 4 integrins and VCAM-1. As previously reported, antibody against beta 2 integrins also partially inhibited transmigration in response to FMLP, but this effect was surprisingly small. Essentially identical results were obtained when IL-8 was used as a chemoattractant in place of FMLP (data not shown).


View larger version (42K):
[in this window]
[in a new window]
 
Fig. 5.   Transmigration of neutrophils across activated HUVE cell monolayers. Purified human neutrophils that had been incubated with no antibody or antibody to alpha 9beta 1 (Y9A2, 10 µg/ml), alpha 4beta 1 (100226, 10 µg/ml), beta 2 (IB4, 20 µg/ml), a combination of these antibodies, or human MHC (W6/32, 10 µg/ml) were added to the top chambers above microporous chambers containing confluent monolayers of HUVE cells that had been incubated with (A) or without TNF-alpha (3 ng/ml; B) for 24 h. DMEM containing FMLP (10 nM) or DMEM alone was added to the bottom chamber. After 3 h at 37°C in 5% CO2, neutrophils that had migrated across the monolayer were collected from the bottom chamber and counted. In additional chambers, untreated neutrophils were added to HUVE cells that had been preincubated for 15 min with antibody to VCAM-1 (CD106, 5 µg/ml). Data are expressed as the mean (+ SD) of quadruplicate measurements from two separate experiments.

    Discussion
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

The results of the current study demonstrate that the inducible endothelial cell immunoglobulin family member, VCAM-1, is an effective ligand for the integrin alpha 9beta 1. This receptor-ligand interaction is sufficient to support adhesion of alpha 9-transfected cell lines to VCAM-1 and to TNF-alpha -activated HUVE cells, an effect that is mediated by the binding of alpha 9beta 1 to VCAM-1. Furthermore, alpha 9beta 1 is uniformly and specifically expressed on normal resting human neutrophils, and mediates both neutrophil migration on a fragment of tenascin-C or VCAM-1 and transmigration of neutrophils across TNF-alpha -activated endothelial monolayers. Together, these data suggest a previously unsuspected role for alpha 9beta 1 and VCAM-1 in extravasation of neutrophils at sites of acute inflammation.

In addition to alpha 9beta 1, we found detectable, albeit low, levels of the structurally related integrin alpha 4 subunit on resting human neutrophils. This finding is consistent with several previous reports of alpha 4 expression on neutrophils from a variety of species (Issekutz et al., 1996; Gao and Issekutz, 1997; Davenpeck et al., 1998). Although the level of expression of alpha 4 we detected on human neutrophils was one to two orders of magnitude lower than expression on eosinophils, monocytes, and lymphocytes, this low level expression appeared to be biologically significant, since antibody against alpha 4 partially inhibited migration of neutrophils on VCAM-1 and migration across TNF-activated endothelial monolayers. Recently, alpha 4beta 1 has been shown to mediate both neutrophil adhesion to VCAM-1 (Davenpeck et al., 1998) and neutrophil transmigration across fibroblast monolayers (Gao and Issekutz, 1997). As expected, alpha 4 integrins did not contribute to migration on TNfn3RAA, since this fragment of tenascin is not a ligand for either alpha 4 integrin.

Adhesion of activated neutrophils to endothelial cells at sites of inflammation is well known to require the participation of integrins sharing the beta 2 subunit (Arfors et al., 1987) which bind to two other members of the immunoglobulin family expressed on endothelial cells, ICAM-1 (Marlin and Springer, 1987; Diamond et al., 1990) and ICAM-2 (Staunton et al., 1989). ICAM-1 is constitutively expressed on many epithelia, but expression is dramatically induced by a variety of inflammatory stimuli, including TNF-alpha . Our data do not address the role of alpha 9beta 1 or alpha 4 integrins in stable adhesion of neutrophils, since we were not able to maintain adhesion of these cells to any substrate in the presence of beta 2 integrin blocking antibodies. This effect could be due to a critical role of these integrins in adhesion or to an inhibitory signaling pathway through which antibody-mediated ligation of beta 2 integrins inhibits the function of other integrins, such as alpha 9beta 1. However, the mechanisms underlying the subsequent steps in neutrophil extravasation, including detachment from sites of initial adhesion and subsequent migration across the endothelial cell surface and components of the underlying extracellular matrix, are not as well understood. The data in this manuscript suggest, at least in the model system used, that alpha 9beta 1 and alpha 4 integrins are likely to play important roles. Both integrins could contribute to migration across VCAM-1 expressing endothelial cells and shared ligands such as osteopontin (Smith et al., 1996; Bayless et al., 1998), and alpha 9beta 1 could be critical for migration across tenascin-C that is present outside the vasculature at sites of inflammation (Erickson, 1993).

A role for beta 2 integrin-independent processes in neutrophil extravasation in vivo has been suggested by several sets of observations, including studies of neutrophil extravasation into the liver in response to endotoxin (Essani et al., 1997) and neutrophil migration into the alveolar spaces of the lung in response to intratracheal instillation of live bacteria (Doerschuk et al., 1990). Recent studies demonstrating neutrophil extravasation into the lungs and peritoneal cavity in beta 2 integrin knockout mice also demonstrate the importance of mechanisms independent of beta 2 integrins (Mizgerd et al., 1997). The extent to which these events are mediated by alpha 9beta 1 and/or alpha 4 integrins needs to be determined from in vivo studies. We have recently succeeded in generating mice expressing a null mutation in the alpha 9 subunit gene, but these mice die within 10 d of birth (unpublished observation). However, the development of bone marrow chimeras from this line should allow us to directly examine these questions.

In addition to the expression on neutrophils described in this report, alpha 9beta 1 is widely expressed on muscle cells, surface epithelial cells, and hepatocytes (Palmer et al., 1993). It is unclear what role, if any, interactions with VCAM-1 might have at these sites. VCAM-1 has also been reported to be expressed on muscle cells under various conditions (Rosen et al., 1992; Sheppard et al., 1994), so it is conceivable that alpha 9beta 1/VCAM-1 interactions may be biologically significant in muscle as well. Such an effect could explain the apparent contradiction between reports, based on antibody inhibition, that alpha 4beta 1/VCAM-1 binding plays a critical role in myotube formation (Rosen et al., 1992) and the normal muscle development of alpha 4 knockout cells in chimeric mice (Yang et al., 1996), if the alpha 4 knockout led to a developmentally regulated increase in alpha 9beta 1 expression.

In summary, we have identified VCAM-1 as a novel and biologically significant ligand for the integrin alpha 9beta 1, have demonstrated that this integrin is expressed on neutrophils and mediates neutrophil migration on two relevant ligands and neutrophil transmigration across activated endothelial monolayers. These findings support a role for alpha 9beta 1/ VCAM-1 interactions in extravasation of neutrophils at sites of inflammation.

    Footnotes

Address correspondence to Dean Sheppard, Lung Biology Center, UCSF Box 0854, San Francisco, CA 94143. Tel.: (415) 206-5901. Fax: (415) 206-4123. E-mail: deans{at}itsa.ucsf.edu

Received for publication 23 November 1998 and in revised form 24 February 1999.

We thank Amha Atakilit and David Erle for technical and intellectual assistance with flow cytometric analysis.

This work was supported by National Institutes of Health grants HLAI33259, HL47412, HL53949, and HL56385 to D. Sheppard.

    Abbreviations used in this paper

EGM, endothelial cell growth media; FMLP, formyl-methionylleucylphenylalanine; HUVE, human umbilical vein endothelial; ICAM, intercellular adhesion molecule; IFN, interferon; TNF, tumor necrosis factor; VCAM-1, vascular cell adhesion molecule-1.

    References
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

1. Arfors, K., C. Lundberg, L. Lindblom, K. Lundberg, P.G. Beatty, and J.M. Harlan. 1987. A monoclonal antibody to the membrane glycoprotein complex CD18 inhibits polymorphonuclear leukocyte accumulation and plasma leakage in vivo. Blood. 69: 338-340 [Abstract].
2. Bayless, K.J., G.A. Meininger, J.M. Scholtz, and G.E. Davis. 1998. Osteopontin is a ligand for the alpha4beta1 integrin. J. Cell Sci. 111: 1165-1174 [Abstract/Free Full Text].
3. Clements, J.M., P. Newham, M. Shepherd, R. Gilbert, T.J. Dudgeon, L.A. Needham, R.M. Edwards, L. Berry, A. Brass, and M.J. Humphries. 1994. Identification of a key integrin-binding sequence in VCAM-1 homologous to the LDV active site in fibronectin. J. Cell Sci. 107: 2127-2135 [Abstract/Free Full Text].
4. Cooper, D., F.P. Lindberg, J.R. Gamble, E.J. Brown, and M.A. Vadas. 1995. Transendothelial migration of neutrophils involves integrin-associated protein (CD47). Proc. Natl. Acad. Sci. USA. 92: 3978-3982 [Abstract/Free Full Text].
5. Davenpeck, K.L., S.A. Sterbinsky, and B.S. Bochner. 1998. Rat neutrophils express alpha4 and beta1 integrins and bind to vascular cell adhesion molecule-1 (VCAM-1) and mucosal addressin cell adhesion molecule-1 (MAdCAM-1). Blood. 91: 2341-2346 [Abstract/Free Full Text].
6. Diamond, M.S., D.E. Staunton, A.R. de Fougerolles, S.A. Stacker, A.J. Garcia, M.L. Hibbs, and T.A. Springer. 1990. ICAM-1 (CD54): a counter-receptor for Mac-1 (CD11b/CD18). J. Cell Biol. 111: 3129-3139 [Abstract].
7. Doerschuk, C.M., R.K. Winn, H.O. Coxson, and J.M. Harlan. 1990. CD18-dependent and -independent mechanisms of neutrophil adherence in the pulmonary and systemic microvasculature of rabbits. J. Immunol. 114: 2327-2333 .
8. Erickson, H.P.. 1993. Tenascin-C, tenascin-R, tenascin-X: a family of talented proteins in search of functions. Curr. Opin. Cell Biol. 5: 869-876
9. Essani, N.A., M.L. Bajt, A. Farhood, S.L. Vonderfecht, and H. Jaeschke. 1997. Transcriptional activation of vascular cell adhesion molecule-1 gene in vivo and its role in the pathophysiology of neutrophil-induced liver injury in murine endotoxin shock. J. Immunol. 158: 5941-5948 [Abstract].
10. Gao, J.X., and A.C. Issekutz. 1997. The beta 1 integrin, very late activation antigen-4 on human neutrophils can contribute to neutrophil migration through connective tissue fibroblast barriers. Immunology. 90: 448-454
11. Gresham, H.D., L.T. Clement, J.E. Lehmeyer, and F.M. Griffin Jr.. 1986. Simulation of human neutrophil Fc receptor-mediated phagocytosis by a low molecular weight cytokine. J. Immunol. 137: 868-875 [Abstract/Free Full Text].
12. Hynes, R.O.. 1987. Integrins: a family of cell surface receptors. Cell. 48: 549-554
13. Hynes, R.O.. 1992. Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 69: 11-25
14. Issekutz, T.B., M. Miyasaka, and A.C. Issekutz. 1996. Rat neutrophils express very late activation antigen 4 and it mediates migration to arthritic joint and dermal inflammation. J. Exp. Med. 183: 2175-2184 [Abstract].
15. Kent, S.J., S.J. Karlik, C. Cannon, D.K. Hines, T.A. Yednock, L.C. Fritz, and H.C. Horner. 1995. A monoclonal antibody to alpha 4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J. Neuroimmunol. 58: 1-10
16. Marks, P.W., B. Hendey, and F.R. Maxfield. 1991. Attachment to fibronectin or vitronectin makes human neutrophil migration sensitive to alterations in cytosolic free calcium concentration. J. Cell Biol. 112: 149-158 [Abstract].
17. Marlin, S.D., and T.A. Springer. 1987. Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1). Cell. 51: 813-819
18. Mizgerd, J.P., H. Kubo, G.J. Kutkoski, S.D. Bhagwan, K. Scharffetter-Kochanek, A.L. Beaudet, and C.M. Doerschuk. 1997. Neutrophil emigration in the skin, lungs and peritoneum: differential requirements for CD11/CD18 revealed by CD18-deficient mice. J. Exp. Med. 186: 1357-1364 [Abstract/Free Full Text].
19. Palmer, E.L., C. Ruegg, R. Ferrando, R. Pytela, and D. Sheppard. 1993. Sequence and tissue distribution of the integrin alpha 9 subunit, a novel partner of beta 1 that is widely distributed in epithelia and muscle. J. Cell Biol. 123: 1289-1297 [Abstract].
20. Prieto, A.L., G.M. Edelman, and K.L. Crossin. 1993. Multiple integrins mediate cell attachment to cytotactin/tenascin. Proc. Natl. Acad. Sci. USA. 90: 10154-10158 [Abstract].
21. Rosen, G.D., J.R. Sanes, R. La Chance, J.M. Cunningham, J. Roman, and D.C. Dean. 1992. Roles for the integrin VLA-4 and its counter receptor VCAM-1 in myogenesis. Cell. 69: 1107-1119
22. Ruoslahti, E., and M.D. Pierschbacher. 1987. New perspectives in cell adhesion: RGD and integrins. Science. 238: 491-497
23. Schnapp, L.M., N. Hatch, D. Ramos, I.V. Kliminskaya, D. Sheppard, and R. Pytela. 1995. The human integrin alpha 8beta 1 functions as a receptor for tenascin, fibronectin, and vitronectin. J. Biol. Chem. 270: 23196-23202 [Abstract/Free Full Text].
24. Schneider, H., R.P. Harbottle, Y. Yokosaki, J. Kunde, D. Sheppard, and C. Coutelle. 1998. A novel peptide, PLAEIDGIELTY, for the targeting of alpha9/beta1-integrins. FEBS Lett. 429: 269-273
25. Sheppard, A.M., M.D. Onken, G.D. Rosen, P.G. Noakes, and D.C. Dean. 1994. Expanding roles for alpha 4 integrin and its ligands in development. Cell Adhes. Commun 2: 27-43
26. Smith, L.L., H.-K. Cheung, L.E. Ling, J. Chen, D. Sheppard, R. Pytela, and C.M. Giachelli. 1996. Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by alpha 9beta 1 integrin. J. Biol. Chem. 271: 28485-28491 [Abstract/Free Full Text].
27. Staunton, D.E., M.L. Dustin, and T.A. Springer. 1989. Functional cloning of ICAM-2, a cell adhesion ligand for LFA-1 homologous to ICAM-1. Nature. 339: 61-64
28. Wang, A., Y. Yokosaki, R. Ferrand, J. Balmas, and D. Sheppard. 1996. Differential regulation of airway epithelial integrins by growth factors. Am. J. Respir. Cell Mol. Biol. 15: 664-672 [Abstract].
29. Yang, J.T., T.A. Rando, W.A. Mohler, H. Rayburn, H.M. Blau, and R.O. Hynes. 1996. Genetic analysis of alpha 4 integrin functions in the development of mouse skeletal muscle. J. Cell Biol. 135: 829-835 [Abstract].
30. Yednock, T.A., C. Cannon, C. Vandevert, E.G. Goldbach, G. Shaw, D.K. Ellis, C. Liaw, L.C. Fritz, and L.I. Tanner. 1995. Alpha 4 beta 1 integrin-dependent cell adhesion is regulated by a low affinity receptor pool that is conformationally responsive to ligand. J. Biol. Chem. 270: 28740-28750 [Abstract/Free Full Text].
31. Yokosaki, Y., E.L. Palmer, A.L. Prieto, K.L. Crossin, M.A. Bourdon, R. Pytela, and D. Sheppard. 1994. The integrin alpha 9beta 1 mediates cell attachment to a non-RGD site in the third fibronectin type III repeat of tenascin. J. Biol. Chem. 269: 26691-26696 [Abstract/Free Full Text].
32. Yokosaki, Y., H. Monis, J. Chen, and D. Sheppard. 1996. Differential effects of the integrins alpha 9beta 1, alpha vbeta 3, and alpha vbeta 6 on cell proliferative responses to tenascin. Roles of the beta  subunit extracellular and cytoplasmic domains. J. Biol. Chem. 271: 24144-24150 [Abstract/Free Full Text].
33. Yokosaki, Y., N. Matsuura, S. Higashiyama, I. Murakami, M. Obara, M. Yamakido, N. Shigeto, J. Chen, and D. Sheppard. 1998. Identification of the ligand binding site for the integrin alpha9/beta1 in the third fibronectin type III repeat of tenascin-C. J. Biol. Chem. 273: 11423-11428 [Abstract/Free Full Text].

Copyright © 1999 by The Rockefeller University Press.
0021-9525/99/04/413/08 $2.00